Bavarian Nordic Announces Interim Results for the First Three Months of 2026

Bavarian Nordic announced Q1 2026 revenue of DKK 1,058 million, with Travel Health growing 14% year-over-year driven by rabies and chikungunya vaccines, while Public Preparedness declined 53% as expected in a normalized year. The company upgraded its full-year guidance to DKK 5,500-5,700 million revenue with ~28% EBITDA margin following a USD 97 million contract award from the U.S. Government for freeze-dried smallpox vaccine production.

05/13/2026, 1:35 AM • GlobeNewswire

Bavarian Nordic offentliggør delårsregnskab for første kvartal 2026

Bavarian Nordic reported Q1 2026 revenue of DKK 1,058 million, with Travel Health growing 14% driven by rabies and chikungunya vaccines, while Public Preparedness declined 53% as expected in a normalized year. The company upgraded full-year guidance to DKK 5,500-5,700 million revenue with ~28% EBITDA margin following a USD 97 million contract award from the U.S. government for freeze-dried smallpox vaccine production.

05/13/2026, 1:35 AM • GlobeNewswire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic A/S has completed additional share repurchase transactions under its DKK 200 million buy-back program launched on March 12, 2026. As of May 1, 2026, the company has accumulated 900,295 repurchased shares at an average price of DKK 190.54, totaling DKK 171.5 million. Bavarian Nordic now holds 2,598,056 treasury shares, representing 3.28% of its share capital.

05/04/2026, 4:45 AM • GlobeNewswire

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic A/S has completed additional share repurchases under its DKK 200 million buy-back program initiated on March 12, 2026. Between April 27 and May 1, 2026, the company repurchased 74,299 shares at an average price of DKK 185.62, bringing total accumulated repurchases to 900,295 shares (3.28% of share capital) valued at DKK 171.5 million.

05/04/2026, 4:45 AM • GlobeNewswire

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic A/S has completed additional share repurchases under its DKK 200 million buy-back program initiated on March 12, 2026. Between April 20-24, 2026, the company repurchased 179,730 shares at an average price of DKK 191.09, bringing total accumulated repurchases to 825,996 shares (3.19% of share capital) worth DKK 157.8 million.

04/27/2026, 2:57 AM • GlobeNewswire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic A/S has announced transactions under its share buy-back program launched on March 12, 2026. Between April 20-24, 2026, the company repurchased 179,730 shares at an average price of 191.09 DKK, bringing total accumulated repurchases to 825,996 shares worth 157.8 million DKK. The company now holds 2,523,757 treasury shares, representing 3.19% of its share capital.

04/27/2026, 2:57 AM • GlobeNewswire

Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S

Bavarian Nordic held its Annual General Meeting on April 21, 2026, adopting the 2025 Annual Report and approving most proposals including board elections, auditor re-election, and authorizations for share issuance and buybacks. However, the Remuneration Report for 2025 failed to gain approval in an indicative vote, prompting the board to discuss the decision and provide an explanatory statement in the 2026 report.

04/21/2026, 2:39 PM • GlobeNewswire

Beslutninger på den ordinære generalforsamling 2026 i Bavarian Nordic A/S

Bavarian Nordic A/S held its annual general meeting on April 21, 2026, approving the 2025 annual report and granting discharge to the board and management. The compensation report was rejected in a non-binding vote, prompting the board to review the decision. The board was expanded to seven members with three new appointments, and shareholders approved authorizations for capital increases, convertible bonds, warrants, and share buybacks. KPMG was reelected as auditor.

04/21/2026, 2:39 PM • GlobeNewswire

Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine

Bavarian Nordic announced that Swissmedic has approved VIMKUNYA, its recombinant chikungunya vaccine, for individuals aged 12 and above. This marks the fourth regulatory approval for the vaccine following FDA, EMA, and MHRA approvals in 2025. The company has also submitted an application to Health Canada for potential approval in the first half of 2026.

04/16/2026, 1:30 AM • GlobeNewswire

Bavarian Nordics chikungunyavaccine er blevet godkendt af de schweiziske lægemiddelmyndigheder

Bavarian Nordic announced that Switzerland's Swissmedic has approved VIMKUNYA, a single-dose chikungunya vaccine for individuals aged 12 and older. This marks the fourth regulatory approval for the vaccine following FDA, EMA, and MHRA approvals in 2025. The company has also submitted an application to Health Canada for potential approval in the first half of 2026.

04/16/2026, 1:30 AM • GlobeNewswire

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic A/S has initiated a share buyback program on March 12, 2026, repurchasing shares for up to DKK 200 million through May 13, 2026. As of March 13, the company has repurchased 40,086 shares at an average price of DKK 177.15, bringing total owned shares to 1,737,847 (2.19% of share capital).

03/16/2026, 5:53 AM • GlobeNewswire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic A/S announced transactions under its share buy-back program launched on March 12, 2026, with authorization to repurchase shares up to DKK 200 million through May 13, 2026. As of March 13, 2026, the company has repurchased 40,086 shares at an average price of DKK 177.15, bringing total treasury shares to 1,737,847 (2.19% of share capital).

03/16/2026, 5:53 AM • GlobeNewswire

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

Bavarian Nordic has signed an exclusive distribution agreement with Eurofarma to sell its chikungunya vaccine (CHIKV VLP) in Brazil, with potential expansion to the rest of Latin America. The agreement is transfer price and royalty-based with no upfront payments. Regulatory submission is expected in the first half of 2026, with potential launch in Brazil in the second half of 2027. Brazil accounts for over half of the world's reported chikungunya cases and deaths.

01/23/2026, 2:00 AM • GlobeNewswire

Bavarian Nordic indgår distributionsaftale med Eurofarma for at udvide adgangen til chikungunya-vacciner i Brasilien

Bavarian Nordic has signed an exclusive distribution agreement with Eurofarma to sell and distribute its chikungunya vaccine (CHIKV VLP) in Brazil, with an option for expansion across Latin America. The regulatory submission is expected in the first half of 2026, with potential market launch in Brazil in the second half of 2027. The agreement is structured on transfer pricing and royalties with no upfront payments, and is not expected to have significant economic impact on Bavarian Nordic in the short to medium term.

01/23/2026, 2:00 AM • GlobeNewswire

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic A/S has executed transactions under its share buy-back program initiated on January 7, 2026, repurchasing 189,897 shares at an average price of DKK 198.67 per share for a total value of DKK 37.7 million. The company now holds 1,156,742 treasury shares, representing 1.46% of its share capital. The program will continue through February 13, 2026, with a total budget of DKK 150 million.

01/19/2026, 2:35 AM • GlobeNewswire